Leadership & Pay ·
On August 14, 2026, Halozyme Therapeutics, Inc. announced the election of Dannielle Appelhans to its Board of Directors
HALOHalozyme Therapeutics, Inc.
On August 14, 2026, Halozyme Therapeutics, Inc. announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans was elected to a class of directors with terms ending at the annual meeting in 2028 and was not initially assigned to any board committee. She will receive compensation under the company's standard non-employee director program, including cash retainers, restricted stock, and stock options. The filing confirms there are no arrangements or related person transactions associated with her election. Halozyme Therapeutics operates in the biotechnology industry, focusing on drug delivery technologies.